Paul Matteis is ranked #945 on 13Foresight, scored on hit rate, average return versus the market, and number of calls.

STIF

Paul Matteis

Q: How accurate are Paul Matteis's stock ratings?

About 51% of Paul's ratings were profitable over a one-year hold, with an average return of +9.2% per rating, measured by 13Foresight from historical prices.

Stifel Nicolaus

Wall Street Analyst

★★★★☆

#945

on 13Foresight · ranked by our own returns

51%

Success Rate

+9.2%

Average Return

48 of 94 calls profitable · +32.1% vs benchmark

Time Frame ⓘ

1 Yr 2 Yr 3 Yr 5 Yr

Compared To ⓘ

S&P 500 (SPY)

📈 Across the calls we could measure, roughly 51% of Paul Matteis's ratings turned a profit when each position was held for 1 year — averaging +9.2% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

137 Buy 39 Hold 0 Sell

Paul's Stock Coverage 41 ratings · 2026-09-29

Company	Date	Position	Consensus ⓘ	Price Target ⓘ	1-Yr Return	vs S&P 500 ⓘ
VRTX Vertex Pharmaceuticals	Sep 22, 2026	HOLD	Strong Buy -15.6% avg upside 62 analysts	—	+2.2%	·
XENE Xenon	Sep 18, 2026	BUY	Strong Buy +53.8% avg upside 28 analysts	—	-7.6%	·
RAPP Rapport Therapeutics, Inc.	Sep 16, 2026	BUY	Strong Buy +74.2% avg upside 14 analysts	$56.00 69.76% Upside	-19.5%	·
DFTX Definium Therapeutics	Sep 15, 2026	BUY	Strong Buy +39.8% avg upside 23 analysts	$67.00 82.57% Upside	+4.3%	·
SION Sionna Therapeutics, Inc.	Sep 15, 2026	HOLD	Buy +320.4% avg upside 12 analysts	$7.00 36.54% Upside	-25.1%	·
CTNM Contineum Therapeutics, Inc. Class A	Sep 15, 2026	BUY	Strong Buy +63.9% avg upside 9 analysts	$28.00 116.77% Upside	-9.1%	·
KRSA Korsana Biosciences	Sep 14, 2026	BUY	Strong Buy +22.1% avg upside 6 analysts	$43.00 43.30% Upside	+17.6%	·
DYN Dyne Therapeutics	Sep 08, 2026	BUY	Strong Buy +130.5% avg upside 31 analysts	$37.00 133.67% Upside	-20.3%	·
BMRN BioMarin Pharmaceutical	Aug 31, 2026	HOLD	Strong Buy +61.1% avg upside 52 analysts	$70.00 17.81% Upside	-8.7%	·
ALNY Alnylam Pharma	Aug 31, 2026	BUY	Strong Buy +24.9% avg upside 51 analysts	$318.00 26.16% Upside	+6.1%	·
QURE uniQure	Aug 13, 2026	BUY	Strong Buy +55.2% avg upside 29 analysts	$71.00 88.12% Upside	-9.1%	·
SPTX Seaport Therapeutics, Inc.	Aug 13, 2026	BUY	Strong Buy +90.8% avg upside 8 analysts	$30.00 47.50% Upside	-9.2%	·
LBRX LB Pharmaceuticals, Inc.	Aug 13, 2026	BUY	Strong Buy +39.6% avg upside 8 analysts	$53.00 42.48% Upside	-15.7%	·
PEPG PepGen Inc.	Aug 13, 2026	BUY	Strong Buy +312.8% avg upside 9 analysts	$12.00 373.35% Upside	-13.1%	·
CMPS COMPASS Pathways	Aug 13, 2026	BUY	Strong Buy +67.7% avg upside 20 analysts	$21.00 58.86% Upside	-0.5%	·
NGNE Neurogene	Aug 13, 2026	BUY	Strong Buy +71.5% avg upside 23 analysts	$46.00 65.49% Upside	-20.5%	·
DNLI Denali Therapeutics	Aug 07, 2026	BUY	Strong Buy +87.7% avg upside 24 analysts	$41.00 100.58% Upside	-15.5%	·
GHRS GH Research	Aug 06, 2026	BUY	Strong Buy +69.5% avg upside 12 analysts	$38.00 63.55% Upside	-23.6%	·
ACAD ACADIA Pharmaceuticals	Aug 05, 2026	HOLD	Strong Buy +76.2% avg upside 43 analysts	$25.00 22.48% Upside	-29.5%	·
BIIB Biogen	Aug 02, 2026	BUY	Strong Buy +11.7% avg upside 53 analysts	$242.00 6.12% Upside	+12.8%	·
IONS Ionis Pharmaceuticals	Aug 02, 2026	HOLD	Strong Buy +65.4% avg upside 43 analysts	$68.00 49.03% Upside	-18.3%	·
NBIX Neurocrine	Jul 31, 2026	BUY	Strong Buy +34.0% avg upside 37 analysts	$215.00 54.61% Upside	-15.8%	·
ALKS Alkermes	Jul 25, 2026	BUY	Strong Buy +8.8% avg upside 34 analysts	$63.00 56.74% Upside	-22.5%	·
LXEO Lexeo Therapeutics, Inc.	Jul 06, 2026	BUY	Strong Buy +509.4% avg upside 11 analysts	$17.00 428.73% Upside	-28.0%	·
VTGN VistaGen Therapeutics	Jul 06, 2026	HOLD	Hold +848.6% avg upside 8 analysts	$1.00 251.22% Upside	+8.0%	·
RYTM Rhythm Pharmaceuticals	Jun 15, 2026	BUY	Strong Buy +26.5% avg upside 22 analysts	$133.00 38.99% Upside	+10.0%	·
MPLT MapLight Therapeutics, Inc.	Jun 02, 2026	BUY	Strong Buy +182.3% avg upside 13 analysts	$36.00 247.86% Upside	-61.7%	·
IMUX Immunic	May 28, 2026	BUY	Strong Buy +307.8% avg upside 22 analysts	$25.00 168.83% Upside	-37.6%	·
NMRA Neumora Therapeutics, Inc.	May 12, 2026	HOLD	Buy +1001.9% avg upside 11 analysts	$3.00 324.07% Upside	-64.3%	·
ANRO Alto Neuroscience, Inc.	Apr 02, 2026	BUY	Strong Buy +20.0% avg upside 13 analysts	$33.00 23.90% Upside	+23.6%	·
ALEC Alector	Dec 22, 2025	HOLD	Hold +418.0% avg upside 15 analysts	—	+32.4%	·
ABOS Acumen Pharmaceuticals	Dec 16, 2025	BUY	Strong Buy +262.2% avg upside 10 analysts	$10.00 351.37% Upside	+9.8%	·
LONA LeonaBio	Sep 19, 2024	HOLD	Buy +272.8% avg upside 9 analysts	—	-16.8%	·
CLYM Climb Bio	Jun 03, 2023	BUY	Strong Buy +87.3% avg upside 20 analysts	$5.00 57.17% Downside	+182.7%	·
WVE Wave Life Sciences	May 12, 2022	HOLD	Strong Buy +467.1% avg upside 29 analysts	$3.00 18.29% Downside	+207.8%	·
IRON Disc Medicine	Feb 28, 2022	HOLD	Strong Buy +36.7% avg upside 21 analysts	$20.00 68.76% Downside	-38.7%	·
OBSEF ObsEva	Aug 16, 2017	BUY	Buy +367199900.0% avg upside 8 analysts	$18.00 1799999899.97% Upside	·	·
NBRVF Nabriva Therapeutics	Mar 10, 2017	BUY	Buy +13374900.0% avg upside 9 analysts	$20.00 19999900.05% Upside	·	·
ACIU AC Immune SA	Nov 23, 2016	BUY	Strong Buy +206.5% avg upside 5 analysts	—	-1.4%	·
FATE Fate Therapeutics	Jun 20, 2016	BUY	Buy +418.7% avg upside 31 analysts	—	+49.0%	·
TPST Tempest Therapeutics	May 06, 2016	HOLD	Buy +2493.3% avg upside 18 analysts	$7.00 770.16% Upside	·	·

🔒 36 more ratings — with price targets, crowd consensus and our measured returns.

Free account unlocks every analyst's full coverage table.

Paul Matteis — Frequently Asked Questions

How accurate are Paul Matteis's stock ratings?

Based on the calls 13Foresight could measure, about 51% of Paul's ratings were profitable over a one-year hold, with an average return of +9.2% per rating, or +32.2% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.

How is Paul ranked on 13Foresight?

Paul Matteis is currently ranked #945 with a 4-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.

Which stocks does Paul cover?

Paul most recently has ratings on VRTX, XENE, RAPP, DFTX, SION, CTNM, KRSA, DYN, BMRN, ALNY, QURE, SPTX and 29 more. See the full coverage table above for positions, price targets and our measured returns.

Where can I see other analyst ratings?

Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.

Paul Matteis

Rating Distribution

Welcome to 13Foresight!